论文部分内容阅读
目的:观察应用盐酸羟考酮控释片(TM)口服和经直肠不同途径给药对中重度癌性疼痛的疗效和不良反应。方法:61例伴有中重度疼痛的癌症患者随机分A组(口服TM)31例和B组(经直肠应用TM)30例。分别应用≤60m g/d和>60 m g/d两个剂量组,对TM的不同程度疼痛的疗效和不良反应进行观察。结果:A组患者维持剂量≤60 m g/d和>60 m g/d的有效率分别为83.3%、85.7%,而B组患者分别为81.8%、87.5%,两组无明显差异(P>0.05);并且进一步对A、B两组不同的疼痛分级、不同的疼痛类型的止痛效果分析,均无统计学差异(P>0.05);另外,A、B两组的不良反应如恶心、呕吐、便秘、排尿困难、嗜睡等均无统计学差异(P>0.05)。结论:经口服和直肠应用TM的疗效和不良反应相近,对重症且进食、进水、吞咽困难者或肠道肿瘤致肠梗阻者经直肠应用TM是有效、安全、方便的镇痛方法之一。
OBJECTIVE: To observe the curative effect and adverse reactions of oxycodone hydrochloride controlled-release tablets (TM) administered orally and rectally by different routes on moderate to severe cancerous pain. Methods: Totally 61 patients with moderate-severe pain were randomly divided into group A (oral TM) and group B (rectal TM) 30 cases. The therapeutic effects and adverse reactions of different degrees of pain were observed in two dose groups of ≤60m g / d and> 60m g / d, respectively. Results: The effective rates of maintenance dose ≤60 mg / d and> 60 mg / d in group A were 83.3% and 85.7% respectively, while those in group B were 81.8% and 87.5% respectively, with no significant difference between the two groups (P> 0.05 ), And further analysized the analgesic effect of different pain grades of A and B groups (P> 0.05). In addition, adverse reactions of A and B groups such as nausea and vomiting, Constipation, dysuria, drowsiness and so on had no statistical difference (P> 0.05). CONCLUSIONS: Oral and rectal applications of TM have similar curative effects and adverse reactions. Rectal TM is an effective, safe and convenient method of analgesia for critically ill patients who have difficulty eating, drinking, swallowing, or intestinal tumor .